Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …

The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces
diverse extracellular signals to protein networks that control proliferation, survival, migration …

DNA microarrays have been widely applied to cancer transcriptome analysis; however, the
majority of such data are not easily accessible or comparable. Furthermore, several …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

The aging of tissue-specific stem cell and progenitor cell compartments is believed to be
central to the decline of tissue and organ integrity and function in the elderly. Here, we …

More complete knowledge of the molecular mechanisms underlying cancer will improve
prevention, diagnosis and treatment. Efforts such as The Cancer Genome Atlas are …

Combinatorial control of biological processes, in which redundancy and multifunctionality
are the norm, fundamentally limits the therapeutic index that can be achieved by even the …

ABL-family proteins comprise one of the best conserved branches of the tyrosine kinases.
Each ABL protein contains an SH3-SH2-TK (Src homology 3–Src homology 2–tyrosine …